Kura Oncology (NASDAQ:KURA - Get Free Report) was downgraded by StockNews.com from a "hold" rating to a "sell" rating in a research note issued on Wednesday.
Several other equities analysts also recently issued reports on the stock. JMP Securities reissued a "market outperform" rating and set a $32.00 price target on shares of Kura Oncology in a report on Tuesday. Wedbush reiterated an "outperform" rating and set a $37.00 target price on shares of Kura Oncology in a research report on Monday, November 4th. Lifesci Capital raised shares of Kura Oncology to a "strong-buy" rating in a research note on Tuesday, October 22nd. Stifel Nicolaus cut shares of Kura Oncology from a "buy" rating to a "hold" rating and reduced their price target for the stock from $26.00 to $19.00 in a research report on Monday, October 14th. Finally, UBS Group initiated coverage on Kura Oncology in a research report on Thursday, October 24th. They set a "buy" rating and a $27.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $28.83.
View Our Latest Research Report on KURA
Kura Oncology Stock Performance
Shares of Kura Oncology stock traded down $0.05 during trading on Wednesday, reaching $15.91. The company's stock had a trading volume of 904,670 shares, compared to its average volume of 893,680. Kura Oncology has a one year low of $9.06 and a one year high of $24.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -6.74 and a beta of 0.86. The business's fifty day moving average price is $18.28 and its 200-day moving average price is $19.82.
Hedge Funds Weigh In On Kura Oncology
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC boosted its position in Kura Oncology by 29.2% in the first quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company's stock valued at $82,120,000 after buying an additional 870,000 shares in the last quarter. Suvretta Capital Management LLC raised its stake in Kura Oncology by 8.2% during the third quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company's stock worth $149,535,000 after buying an additional 583,155 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Kura Oncology by 50.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company's stock valued at $35,653,000 after purchasing an additional 577,732 shares during the period. Affinity Asset Advisors LLC boosted its holdings in shares of Kura Oncology by 281.4% during the 1st quarter. Affinity Asset Advisors LLC now owns 730,492 shares of the company's stock worth $15,581,000 after buying an additional 538,957 shares in the last quarter. Finally, Sofinnova Investments Inc. increased its stake in Kura Oncology by 64.4% in the second quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company's stock valued at $16,992,000 after purchasing an additional 323,303 shares in the last quarter.
About Kura Oncology
(
Get Free Report)
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
See Also
Before you consider Kura Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kura Oncology wasn't on the list.
While Kura Oncology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
